AstraZeneca plc (NYSE:AZN) was downgraded by stock analysts at Goldman Sachs from a “neutral” rating to a “sell” rating in a note issued to investors on Monday, The Fly reports.
Other hedge funds have made changes to their positions in the company. HHG & Company increased its stake in shares of AstraZeneca plc by 0.4% in the fourth quarter. HHG & Company now owns 23,367 shares of the biopharmaceutical company’s stock valued at $793,000 after buying an additional 85 shares during the last quarter. Baird Financial Group Inc. increased its stake in shares of AstraZeneca plc by 0.3% in the fourth quarter. Baird Financial Group Inc. now owns 60,888 shares of the biopharmaceutical company’s stock valued at $2,067,000 after buying an additional 200 shares during the last quarter. FirstMerit Bank increased its stake in shares of AstraZeneca plc by 5.0% in the fourth quarter. FirstMerit Bank now owns 9,664 shares of the biopharmaceutical company’s stock valued at $328,000 after buying an additional 458 shares during the last quarter. Emerson Investment Management LLC increased its stake in shares of AstraZeneca plc by 0.5% in the fourth quarter. Emerson Investment Management LLC now owns 98,830 shares of the biopharmaceutical company’s stock valued at $3,355,000 after buying an additional 535 shares during the last quarter. Finally, Garrison Financial Corp increased its stake in shares of AstraZeneca plc by 6.0% in the fourth quarter. Garrison Financial Corp now owns 18,037 shares of the biopharmaceutical company’s stock valued at $612,000 after buying an additional 1,020 shares during the last quarter.
Source: American Banking and Market News